Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

INSIGHT 2: a phase II study of tepotinib plus osimertinib in -amplified NSCLC and first-line osimertinib resistance.

Autor: F Smit, Egbert, Dooms, Christophe, Raskin, Jo, Nadal, Ernest, Tho, Lye M, Le, Xiuning, Mazieres, Julien, S Hin, How, Morise, Masahire, W Zhu, Viola, Tan, Daniel, H Holmberg, Kristina, Ellers-Lenz, Barbara, Adrian, Svenja, Brutlach, Sabine, Schumacher, Karl M, Karachaliou, Niki, Wu, Yi-Long

Publikováno v: Future Oncology; Apr2022, Vol. 18 Issue 9, p1039-1054, 16p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tepotinib + osimertinib for EGFR mutant (EGFR m) NSCLC with MET amplification (MET amp) after first-line (1L) osimertinib.

Autor: Tan, Daniel Shao-Weng, Kim, Tae Min, Guarneri, Valentina, VOON, PEI JYE, Lim, Boon Khaw, Wislez, Marie, Huang, Cheng, Liam, Chong Kin, Mazieres, Julien, Tho, Lye Mun, Hayashi, Hidetoshi, Nhung, Nguyen, Chia, Puey Ling, de Marinis, Filippo, Le, Xiuning, Karachaliou, Niki, Brutlach, Sabine, Adrian, Svenja, Ellers-Lenz, Barbara, Wu, Yi-Long

Publikováno v: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p9021-9021, 1p

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET -amplified NSCLC and first-line osimertinib resistance.

Autor: F Smit E; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Dooms C; Department of Respiratory Diseases & Respiratory Oncology Unit, University Hospitals Leuven, Leuven, Belgium., Raskin J; Department of Pulmonology & Thoracic Oncology, Antwerp University Hospital (UZA), Edegem, Belgium., Nadal E; Department of Medical Oncology, Catalan Institute of Oncology, L'Hospitalet, Barcelona, Spain., Tho LM; Department of Oncology, Pantai Hospital, Kuala Lumpur, Malaysia., Le X; Department of Thoracic Head & Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA., Mazieres J; CHU de Toulouse, Institut Universitaire du Cancer, Toulouse, France., S Hin H; Hospital Tengku Ampuan Afzan, Pahang, Malaysia., Morise M; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan., W Zhu V; University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, CA, USA., Tan D; Division of Medical Oncology, National Cancer Centre Singapore, Singapore., H Holmberg K; EMD Serono Research & Development Institute, Inc., MA, USA, an affiliate of Merck KGaA., Ellers-Lenz B; Department of Biostatistics, Merck Healthcare KGaA, Darmstadt, Germany., Adrian S; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Brutlach S; Late Stage Development Operations, Merck Healthcare KGaA, Darmstadt, Germany., Schumacher KM; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Karachaliou N; Global Clinical Development, Merck Healthcare KGaA, Darmstadt, Germany., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China.

Publikováno v: Future oncology (London, England) [Future Oncol] 2022 Mar; Vol. 18 (9), pp. 1039-1054. Date of Electronic Publication: 2021 Dec 17.